APT-1011 (Fluticasone ODT) Expanded Access Protocol for Patients

Recruiting

12 years - 99 years

All

75 participants needed

1 Location

Brief description of study

The purpose of this study is to provide study drug APT-1011 to patients with Eosinophilic Esophagitis who have no suitable approved standard therapies for treatment and who are not eligible for other clinical trials. In addition, this program will collect tolerability, safety, and efficacy information.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research,Eosinophilic Esophagitis
Age: 12 years - 99 years
Gender: All

Ages 12+ Diagnosed with Eosinophilic Esophagitis

Updated on 04 Aug 2024. Study ID: 851242

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

APT-1011 (Fluticasone ODT) Expanded Access Protocol for Patients with Eosinophilic Esophagitis

Brief description of study

Eligibility of study

Find a site

Interested in the study